Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|February 2, 2015
- Pharmaceutical Technology-02-02-2015
- Volume 39
- Issue 2
Radio Frequency Dryer Improves Efficiency
Radio Frequency’s Macrowave Dryers feature volumetric heating, moisture reduction, shortened dwell times, and keep temperature uniform throughout temperature-sensitive materials.
Radio Frequency’s Macrowave Dryers feature volumetric heating, moisture reduction as low as 200 PPM, shortened dwell times, and keep temperature uniform throughout temperature-sensitive materials. Bed depths up to six inches experience rapid drying, and with cost-efficiency in mind, the dryer can reduce labor and energy costs by 60%. The dryer is designed for conveyorized applications and features instant on/off power control.
Radio Frequency
Articles in this issue
over 11 years ago
Hiden Analytical Combination Spectrometer Increases Repeatabilityover 11 years ago
Ross Disperser Maintains Consistencyover 11 years ago
FANUC Robot Enhances Cycles Per Secondover 11 years ago
Preventing Tablet Tooling Problemsover 11 years ago
Chiral Resolution with and without Resolving Agentsover 11 years ago
FDA Sets Agenda for 2015 Guidance Developmentover 11 years ago
Cures Require Compromiseover 11 years ago
Ligand-Binding Assays and the Determination of Biosimilarityover 11 years ago
Labeling of Biosimilarsover 11 years ago
FDA Sets Policies to Enhance Drug Security and SafetyRelated to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
PharmTech AI Pulse Check: On-Prem vs. Cloud AI
5